Cognition Therapeutics Inc (NASDAQ: CGTX)

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. The company focuses on developing disease-modifying treatments for patients with Alzheimer's disease, dementia with Lewy bodies, and geographic atrophy secondary to dry age-related macular degeneration. Its lead product candidate, zervimesine, also known as CT1812, is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins including β-amyloid and α-synuclein.

Cognition Therapeutics Inc generates revenue primarily through non-dilutive grant funding to support its clinical development programs, as it has not yet commercialized any products. The company has received approximately $171 million in cumulative grants awarded primarily by the National Institute on Aging to fund its clinical trials for zervimesine across multiple indications. Revenue generation is currently dependent on securing additional grant awards, potential partnerships, and future product sales upon regulatory approval of its pipeline candidates.

The company operates through the following segments:

• Alzheimer's Disease Program: This segment focuses on the development of zervimesine for the treatment of Alzheimer's disease across multiple stages, including mild cognitive impairment and mild-to-moderate Alzheimer's disease. The segment includes clinical trials such as COG0201 (SHINE), COG0203 (START), and COG0202 (SEQUEL), which have evaluated zervimesine's efficacy and safety in patients with Alzheimer's disease. The program has received funding from the National Institute on Aging, including an approximately $81 million grant for the START trial.

• Dementia with Lewy Bodies Program: This segment is dedicated to advancing zervimesine for the treatment of dementia with Lewy bodies, including its psychotic symptoms. The segment includes the completed Phase 2 COG1201 (SHIMMER) trial in 130 patients with mild-to-moderate dementia with Lewy bodies and the ongoing expanded access program COG1202. The SHIMMER trial was funded by a grant of approximately $30 million from the National Institute on Aging and showed efficacy signals across behavioral, functional, cognitive, and motor scales.

• Geographic Atrophy Secondary to Dry AMD Program: This segment explored the use of zervimesine for the treatment of geographic atrophy secondary to dry age-related macular degeneration. The segment included the Phase 2 COG2201 (MAGNIFY) study, which enrolled approximately 100 participants before being voluntarily concluded in January 2025 to conserve company resources for dementia programs. Topline results from the MAGNIFY study showed zervimesine treatment slowed geographic atrophy lesion growth rates by 29% compared to placebo.

Cognition Therapeutics Inc is positioned as an innovator in the neurodegenerative disease therapeutics space with a differentiated small molecule approach targeting synaptic protection, distinguishing it from monoclonal antibody therapies currently approved for Alzheimer's disease. The company faces competition from large pharmaceutical and biotechnology companies such as Eisai, Eli Lilly, and Biogen, which have approved disease-modifying treatments for Alzheimer's disease, but lacks direct competitors in the dementia with Lewy bodies psychosis space where no disease-modifying therapies are currently approved. Its competitive advantages include its novel mechanism of action involving S2R complex modulation, strong preclinical and clinical evidence of target engagement, and substantial non-dilutive funding from the National Institute on Aging supporting its clinical development.

Cognition Therapeutics Inc serves patients suffering from age-related neurodegenerative disorders, including individuals with Alzheimer's disease, dementia with Lewy bodies, and geographic atrophy secondary to dry age-related macular degeneration. The company's clinical trials enroll participants diagnosed with mild cognitive impairment, early-stage Alzheimer's disease, mild-to-moderate Alzheimer's disease, mild-to-moderate dementia with Lewy bodies, and geographic atrophy, with study sites located across the United States through collaborations with networks such as the Alzheimer's Clinical Trial Consortium.